RecruitingPhase 1Phase 2NCT06795412

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Sponsor

Pyxis Oncology, Inc

Enrollment

220 participants

Start Date

Apr 15, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called PYX-201 and a drug called pembrolizumab for people with advanced solid tumors. The study is currently recruiting participants at 19 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPYX-201

Intravenous (IV) infusion.

DRUGpembrolizumab

IV infusion.

Locations(22)

University of California San Diego

San Diego, California, United States

Sarcoma Oncology Center

Santa Monica, California, United States

Moffitt Cancer Center

Tampa, Florida, United States

University of Chicago

Chicago, Illinois, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Stephenson Cancer Center - University of Oklahoma

Oklahoma City, Oklahoma, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

University of Texas - M.D. Anderson Cancer Center

Houston, Texas, United States

NEXT Oncology Houston

Houston, Texas, United States

NEXT Virginia

Fairfax, Virginia, United States

Hopital Saint - Andre - CHU de Bordeaux

Bordeaux, France

Centre Léon Bérard

Lyon, France

Hôpital de la Timone

Marseille, France

Institut Gustave Roussy

Villejuif, France

Hospital Universitario Vall d'Hebron

Barcelona, Spain

Hospital Universitario Ramón y Cajal

Madrid, Spain

START Madrid - Hospital Universitario Fundación Jiménez Díaz

Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Clínico Universitario de Valencia

Valencia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06795412

Related Trials

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT07435038

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT0600424538 locations

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

NCT073495379 locations

A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors

NCT066052221 location

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

NCT067990656 locations